abt-288
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00888693)
Timeline
Indications
Mechanism of action
- Histamine H3 receptorANTAGONIST
HRH3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CN1CC2CCN(c3ccc(-c4ccc(-n5ncccc5=O)cc4)cc3)C2C1- Mol. weight
- 372.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545029 ↗
Also known as
- 2-(4'-(5-methylhexahydropyrrolo(3,4-b)pyrrol-1-yl)biphenyl-4-yl)-2h-pyridazin-3-one
- abt-288
- abt-288
- abt-288
- abt-288
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01077700 | Phase 2 | Mar 1, 2010 | AbbVie |
| NCT01018875 | Phase 2 | Dec 1, 2009 | AbbVie |
| NCT00888693 | Phase 1 | Nov 1, 2008 | Abbott |
Showing 3 of 3 trials
Page 1 / 1